|
Acton Pharma Says Trial Of Asthma Therapy Aerospan Shows No Growth Suppression
RTT News (RTTNews) – Privately-held Acton Pharmaceuticals Inc. Tuesday reported the publication of results of the Phase IIIb trial of Aerospan, a long-term asthma therapy, which said no suppression of growth and bone maturation was found in prepubescent … Acton Pharmaceuticals, Inc. Announces Publication of AEROSPAN(R) (Flunisolide … |
View full post on asthma – Google News